Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial - Landray, M; Haynes, R; Hopewell, J; Parish, S; Aung, T; Tomson, J; Wallendszus, K; Craig, M; Jiang, L; Landray, M; Collins, R (New England Journal of Medicine, 2014)